scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.JOMS.2014.04.031 |
P698 | PubMed publication ID | 25234529 |
P50 | author | Thomas B Dodson | Q95336517 |
John E Fantasia | Q98936044 | ||
P2093 | author name string | Tara Aghaloo | |
Bhoomi Mehrotra | |||
Reginald Goodday | |||
Felice O'Ryan | |||
Salvatore L. Ruggiero | |||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | position paper | Q7233193 |
P304 | page(s) | 1938-1956 | |
P577 | publication date | 2014-10-01 | |
P1433 | published in | Journal of Oral and Maxillofacial Surgery | Q6295692 |
P1476 | title | American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update | |
P478 | volume | 72 |
Q36340765 | A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors |
Q42319484 | A Case of Bisphosphonate-Related Osteonecrosis of the Jaw in a Patient with Subpontic Osseous Hyperplasia |
Q38468208 | A Case of Brain Abscess Caused by Medication-Related Osteonecrosis of the Jaw. |
Q47120536 | A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab |
Q40064245 | A Case of Pentastomiasis at the Left Maxilla Bone in a Patient with Thyroid Cancer. |
Q91962788 | A Novel, Tumor-Induced Osteoclastogenesis Pathway Insensitive to Denosumab but Interfered by Cannabidiol |
Q55256056 | A SERM increasing the expression of the osteoblastogenesis and mineralization-related proteins and improving quality of bone tissue in an experimental model of osteoporosis. |
Q57459606 | A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw |
Q47252665 | A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer |
Q87940374 | A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent M |
Q90392351 | A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants |
Q36360226 | A rare case of osteonecrosis of the jaw related to imatinib |
Q40490169 | A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians |
Q64989421 | A summary of the Malaysian Clinical Guidance on the management of postmenopausal and male osteoporosis, 2015. |
Q36760348 | Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? |
Q64935046 | Adipose-derived stem cells prevent the onset of bisphosphonate-related osteonecrosis of the jaw through transforming growth factor β-1-mediated gingival wound healing. |
Q39130990 | Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. |
Q90066061 | Adjuvant denosumab in early breast cancer - Authors' reply |
Q90014839 | Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review |
Q53773544 | Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned. |
Q88466609 | Aggressive denosumab-related jaw necrosis - a case series |
Q60910319 | Allogeneic multipotent mesenchymal stromal cell sheet transplantation promotes healthy healing of wounds caused by zoledronate and dexamethasone in canine mandibular bones |
Q52663393 | Altered macrophagic THP-1 cell phagocytosis and migration in bisphosphonate-related osteonecrosis of the jaw (BRONJ). |
Q42290498 | An elderly with a 'bony' smile |
Q102059139 | An impossible choice: MRONJ vs ORN? The difficulties of the decision-making process for head and neck cancer patients on long-term anti-angiogenic medication |
Q41019775 | An osteonecrosis model induced by oral bisphosphonate in ovariectomised rats. |
Q41570205 | An unusual case of disappearing bone disease in the mandible and literature review |
Q39029480 | Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates |
Q35906730 | Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events |
Q55265048 | Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview. |
Q55244759 | Anti-inflammatory effect of polydeoxyribonucleotide on zoledronic acid-pretreated and lipopolysaccharide-stimulated RAW 264.7 cells. |
Q91671918 | Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries |
Q30239854 | Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. |
Q90145052 | Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients |
Q47732074 | Antiresorptive treatment-associated ONJ. |
Q36753894 | Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents |
Q89921984 | Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners |
Q27026718 | Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral [...] |
Q39299999 | Beyond ONJ - A review of the potential uses of bisphosphonates in dentistry |
Q91974441 | Bilateral Bone Ridge Splitting in Maxilla with Immediate Implant Placement in a Patient with Osteoporosis: A Clinical Report with 2-Year Follow-up |
Q41366615 | Bilateral Maxillary Reconstruction Using Fibular Flap in Bisphosphonate-related Osteonecrosis |
Q38538490 | Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare |
Q39034377 | Biomarkers for Bisphosphonate-Related Osteonecrosis of the Jaw. |
Q61453146 | Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review |
Q37087037 | Bisphosphonate Induces Osteonecrosis of the Jaw in Diabetic Mice via NLRP3/Caspase-1-Dependent IL-1β Mechanism |
Q51743699 | Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw. |
Q35877630 | Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking |
Q48283228 | Bisphosphonate guidelines for treatment and prevention of myeloma bone disease |
Q39367690 | Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males |
Q37217791 | Bisphosphonate treatment and dental implants: A systematic review |
Q35755688 | Bisphosphonate uptake in areas of tooth extraction or periapical disease |
Q36299558 | Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation |
Q37626921 | Bisphosphonate-related osteonecrosis of jaws in advanced stage breast cancer was detected from bone scan: a case report |
Q36426563 | Bisphosphonate-related osteonecrosis of the jaw in a patient with osteoporosis following treatment of testicular cancer: a case report |
Q36527045 | Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases |
Q55364153 | Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. |
Q31108809 | Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database |
Q38831851 | Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity. |
Q92976897 | Bisphosphonate-related osteonecrosis. Application of adipose-derived stem cells in an experimental murine model |
Q48136150 | Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis. |
Q38970807 | Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC). |
Q60673746 | Bone-Targeted Agents |
Q47557023 | CT Imaging Features of Antiresorptive agent-Related Osteonecrosis of the Jaw/ Medication-Related Osteonecrosis of the Jaws. |
Q41607133 | Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw? |
Q39062020 | Carcinoma of the lip five years after bone marrow transplantation |
Q58753629 | Case report of maxillofacial fracture in a patient under bisphosphonates in the absence of ONJ disease: Guidelines? |
Q52572107 | Changes in dimension of neurovascular canals in the mandible and maxilla: A radiographic finding in patients diagnosed with MRONJ. |
Q55368042 | Characteristic Multimodal Imaging of Medication-Related Osteonecrosis of the Jaw: Comparison Between Oral and Parenteral Routes of Medication Administration. |
Q36604330 | Chemical and Radiation-Associated Jaw Lesions |
Q92514560 | Clinical analysis of medication related osteonecrosis of the jaws: A growing severe complication in China |
Q92504999 | Clinical and panoramic radiographic features of osteomyelitis of the jaw: A comparison between antiresorptive medication-related and medication-unrelated conditions |
Q58595822 | Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw |
Q55032991 | Clinical impact of bisphosphonates in root canal therapy. |
Q89598542 | Cloud-Based Multicenter Data Collection and Epidemiologic Analysis of Bisphosphonate-Related Osteonecrosis of the Jaws in a Central European Population |
Q47297530 | Collagen sponge and rhBMP-2 improve socket healing in rats treated with zoledronic acid |
Q90353077 | Combined Approach to Treat Medication-Related Osteonecrosis of the Jaws |
Q38490996 | Comments on "diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus". |
Q90676907 | Comparison of Isoflurane, Ketamine-Dexmedetomidine, and Ketamine-Xylazine for General Anesthesia during Oral Procedures in Rice Rats (Oryzomys palustris) |
Q48093177 | Comparison of effects of zoledronic acid and clodronate on the bone structure: imaginological and histomorphometrical study in vivo |
Q88431996 | Comparison of mucosal and mucoperiosteal wound cover for the treatment of medication-related osteonecrosis of the jaw lesions: a retrospective cohort study |
Q92504991 | Computer programme to assess mandibular cortex morphology in cases of medication-related osteonecrosis of the jaw with osteoporosis or bone metastases |
Q38716842 | Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature |
Q49858723 | Conservative Prosthetic Rehabilitation of Medication-Related Osteonecrosis of the Jaw (MRONJ). |
Q58766046 | Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study |
Q96962756 | Conservative non-surgical management in medication related osteonecrosis of the jaw: A retrospective study |
Q54500167 | Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw. |
Q34815134 | Current controversies in classification, management, and prevention of bisphosphonate-related osteonecrosis of the jaw. |
Q90122423 | Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals |
Q57152356 | Cytokine Mixtures Mimicking Secretomes From Mesenchymal Stem Cells Improve Medication-Related Osteonecrosis of the Jaw in a Rat Model |
Q40332532 | DC-STAMP Is an Osteoclast Fusogen Engaged in Periodontal Bone Resorption. |
Q64966398 | Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients. |
Q90714435 | Deciphering novel chemotherapy and its impact on dentistry |
Q87430852 | Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study? |
Q55094789 | Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. |
Q37246486 | Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case. |
Q91999745 | Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial |
Q91013795 | Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. |
Q89052349 | Denosumab treatment in postmenopausal women with osteoporosis |
Q49917811 | Denosumab treatment in postmenopausal women with osteoporosis - Authors' reply |
Q88310017 | Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study |
Q36524611 | Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases |
Q38660112 | Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review |
Q47251973 | Denosumab-related osteonecrosis of the jaw: A retrospective study. |
Q91675370 | Dental care for patients taking antiresorptive drugs: a literature review |
Q37713115 | Dental extraction following zoledronate, induces osteonecrosis in rat's jaw. |
Q38262448 | Dental implants in patients affected by systemic diseases |
Q28080315 | Dental implants in patients treated with antiresorptive medication - a systematic literature review |
Q47149046 | Dental students' knowledge of medication-related osteonecrosis of the jaw. |
Q39636360 | Dental treatments, tooth extractions, and osteonecrosis of the jaw in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study |
Q98226363 | Dentists' knowledge about medication-related osteonecrosis of the jaw and its management |
Q37123301 | Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events |
Q47336736 | Differences between osteoradionecrosis and medication-related osteonecrosis of the jaw. |
Q37408215 | Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw. |
Q57218212 | Distribution of medical status and medications in elderly patients treated with dental implant surgery covered by national healthcare insurance in Korea |
Q46146438 | Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws? |
Q53815592 | EU/IT Multicenter Studies (ON/OFF) and the “DoctOral” System for ONJ. |
Q48172033 | Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice |
Q87422028 | Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis |
Q39434824 | Effect of local zoledronate delivery on osseointegration: a systematic review of preclinical studies |
Q50033823 | Effects of Zoledronic Acid in Experimental Periapical Lesions in Rats: An Imaging and Histological Analysis. |
Q64277342 | Effects of zoledronic acid and dexamethasone on early phases of socket healing after tooth extraction in rats: A preliminary macroscopic and microscopic quantitative study |
Q94565079 | Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review |
Q96431150 | Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature |
Q91892086 | Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy |
Q94571272 | Enhancement of peri-implant bone formation via parathyroid hormone administration in a rat model at risk for medication-related osteonecrosis of the jaw |
Q61810541 | Epidermal Growth Factor Reverses the Inhibitory Effects of the Bisphosphonate, Zoledronic Acid, on Human Oral Keratinocytes and Human Vascular Endothelial Cells In Vitro via the Epidermal Growth Factor Receptor (EGFR)/Akt/Phosphoinositide 3-Kinase (P |
Q36839105 | Evaluation of BP-ONJ in osteopenic and healthy sheep: comparing ZTE-MRI with µCT. |
Q53808348 | Evaluation of a new visual aid for the identification of oral mucosal diseases and conditions. |
Q87273229 | Evaluation of dental implants as a risk factor for the development of bisphosphonate-related osteonecrosis of the jaw in breast cancer patients |
Q53242939 | Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis. |
Q38624057 | Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jaw: Associated clinical characteristics |
Q64265907 | Extensive osteonecrosis of the maxilla caused by bisphosphonates: Report of a rare case |
Q90499876 | Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor? |
Q40690834 | Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw. |
Q90567724 | From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights |
Q64070933 | Gene Variant Causing High Blood Pressure May Be Associated With Medication-related Jaw Osteonecrosis |
Q92859165 | General dental practitioners' perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of Eng |
Q50926376 | Guided bone regeneration in osteoporotic conditions following treatment with zoledronic acid. |
Q35590055 | How concerns for bisphosphonate-induced osteonecrosis of the jaw affect clinical practice among dentists: a study from the South Texas Oral Health Network |
Q38803408 | Hyperbaric oxygen therapy and osteonecrosis |
Q40605141 | IL-36 Induces Bisphosphonate-Related Osteonecrosis of the Jaw-Like Lesions in Mice by Inhibiting TGF-β-Mediated Collagen Expression. |
Q91788229 | Iatrogenic risk of osteonecrosis of the jaw? Bone substitutes for dental implants: a warning from Japan |
Q52909564 | Image findings of bisphosphonate related osteonecrosis of jaws comparing with osteoradionecrosis. |
Q54958018 | Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ). |
Q64081078 | Imaging modalities for drug-related osteonecrosis of the jaw (2), Overview of the position paper on medication-related osteonecrosis of the jaw and the current status of the MRONJ in Japan |
Q89341835 | Imaging of Radiation- and Medication-Related Osteonecrosis |
Q91608582 | Immediate reconstruction of mandibular defect after treatment of medication-related osteonecrosis of the jaw (MRONJ) with rhBMP-2/ACS and miniplate: Review of 3 cases |
Q40696253 | Impact of Osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis (A-TOP) Research Group |
Q47363538 | In-vivo imaging of the microvasculature of the soft tissue margins of osteonecrotic jaw lesions |
Q89795058 | Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease |
Q47672449 | Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors |
Q47325841 | Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. |
Q89936409 | Indigenous Microbiota Protects against Inflammation-Induced Osteonecrosis |
Q49824107 | Influence of the teaching program on the learning in knowledge and practice of osteonecrosis of the jaws produced by antireasorptives in dental students of the Principality of Asturias (Spain). |
Q38393256 | International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15. |
Q51273538 | Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy. |
Q42695284 | Interventions for managing medication-related osteonecrosis of the jaw. |
Q47705261 | Investigation of dental cone-beam CT pixel data and a modified method for conversion to Hounsfield unit (HU). |
Q85476262 | Jaw problems: Update on ARONJ |
Q89596946 | Knowledge and Opinions of Saudi Dentists Regarding Dental Treatment of Patients Undergoing Bisphosphonates |
Q41253737 | Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw. |
Q28583668 | Knowledge of bisphosphonate-related osteonecrosis of the Jawsamong Mexican dentists |
Q50041551 | Laser and Platelet-Rich Plasma to treat Medication-Related Osteonecrosis of the Jaws (MRONJ): a case report |
Q89396612 | Long-term oral bisphosphonates delay healing after tooth extraction: a single institutional prospective study |
Q90047306 | Low-Intensity Pulsed Ultrasound Prevents Development of Bisphosphonate-Related Osteonecrosis of the Jaw-Like Pathophysiology in a Rat Model |
Q52672755 | Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw. |
Q49836028 | MRONJ risk of adjuvant bisphosphonates in early stage breast cancer |
Q53646302 | MRONJ risk reduction pathway - 360 degree survey. |
Q35570290 | Management of bisphosphonate-related osteonecrosis of the jaw: a literature review. |
Q91060388 | Management of bone complications in patients with genitourinary malignancies |
Q38756478 | Managing Intraoral Lesions in Oral Cancer Patients in a General Dental Practice: An Overview |
Q64965457 | Managing tooth pain in general practice. |
Q41844679 | Maxilla Osteonecrosis: a differential diagnosis in patients with metastatic cancer on bisphosphonates |
Q33703167 | Meaning and Limitation of Cortical Bone Width Measurement with DentaScan in Medication-Related Osteonecrosis of the Jaws |
Q89308700 | Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings |
Q36144427 | Medication-Related Osteonecrosis of Jaws: A Low-Level Laser Therapy and Antimicrobial Photodynamic Therapy Case Approach. |
Q28072449 | Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches |
Q37397060 | Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience. |
Q64078469 | Medication-Related Osteonecrosis of the Jaws: Two Center Retrospective Cohort Studies |
Q90449869 | Medication-related Osteonecrosis of the Jaw: A Review |
Q64276494 | Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat |
Q58600670 | Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study |
Q52985345 | Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. |
Q64082139 | Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review |
Q39700905 | Medication-related osteonecrosis of the jaw. Introduction of a new modified experimental model. |
Q52630017 | Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. |
Q26749965 | Medication-related osteonecrosis of the jaw: Clinical and practical guidelines |
Q64982389 | Medication-related osteonecrosis of the jaws after tooth extraction in senescent female mice treated with zoledronic acid: Microtomographic, histological and immunohistochemical characterization. |
Q42324262 | Medication-related osteonecrosis of the jaws caused lethal sepsis in an edentulous patient with multiple systemic factors |
Q48238647 | Medication-related osteonecrosis of the posterior maxilla: surgical treatment using a combined transnasal endoscopic and intraoral approach, our experience with seven consecutive patients |
Q92564261 | Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw |
Q57053962 | Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw |
Q64076859 | Microcirculatory consequences of limb ischemia/reperfusion in ovariectomized rats treated with zoledronic acid |
Q37613671 | Microscopic Evaluation of the Effect of Oral Microbiota on the Development of Bisphosphonate-Related Osteonecrosis of the Jaws in Rats |
Q55426041 | Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review. |
Q55077666 | Minodronate for the treatment of osteoporosis. |
Q90482843 | Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors |
Q39178336 | Modified protocol including topical minocycline in orabase to manage medication-related osteonecrosis of the jaw cases |
Q97538215 | Monitoring indices of bone inflammatory activity of the jaw using SPECT bone scintigraphy: a study of ARONJ patients |
Q36766324 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report |
Q56984566 | Necrotizing fasciitis as a complication of osteonecrosis of the jaw related to oral bisphosphonate application in a patient with osteoporosis: a case report |
Q98564875 | New MRONJ guidance |
Q60922830 | Nitrogen Containing Bisphosphonates Impair the Release of Bone Homeostasis Mediators and Matrix Production by Human Primary Pre-Osteoblasts |
Q89187407 | Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care |
Q64266454 | Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ) |
Q37199204 | OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice. |
Q38585389 | Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis |
Q47567474 | Oral Methotrexate-related Lymphoproliferative Disease Presenting with Severe Osteonecrosis of the Jaw: A Case Report and Literature Review |
Q59465735 | Oral and dental health in head and neck cancer survivors |
Q90465321 | Oral health status of patients with multiple myeloma |
Q38948950 | Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors |
Q88557131 | Oral rehabilitation of the cancer patient: A formidable challenge |
Q40205778 | Oral squamous cell carcinoma arising in a patient after hematopoietic stem cell transplantation with bisphosphonate-related osteonecrosis of the jaws |
Q50061924 | Oral surgery: The drug holiday |
Q47629480 | Osseous changes in patients with medication-related osteonecrosis of the jaws |
Q26827072 | Osteochemonecrosis: an overview |
Q38807483 | Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology |
Q52643968 | Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition. |
Q55332559 | Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature. |
Q35837168 | Osteonecrosis of the Jaw Developed in Mice: DISEASE VARIANTS REGULATED BY γδ T CELLS IN ORAL MUCOSAL BARRIER IMMUNITY. |
Q52620697 | Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India. |
Q90116722 | Osteonecrosis of the Jaw and Concomitant Atypical Femoral Fractures with Bisphosphonates: A Comprehensive Literature Review |
Q57163245 | Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology |
Q40560466 | Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases |
Q41470599 | Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). |
Q55346257 | Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures. |
Q47941432 | Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates. |
Q35818022 | Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. |
Q38865775 | Osteonecrosis of the jaw a new complication related to Ipilimumab. |
Q42373317 | Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark |
Q37525339 | Osteonecrosis of the jaw associated with ziv-aflibercept |
Q51071178 | Osteonecrosis of the jaw in a patient receiving cabozantinib. |
Q88527999 | Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis |
Q36667402 | Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients |
Q37036742 | Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review |
Q57800097 | Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review |
Q42202161 | Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease |
Q99240570 | Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases |
Q61450539 | Osteonecrosis of the jaws caused by bisphosphonate treatment and oxidative stress in mice |
Q64277201 | Osteonecrosis of the jaws produced by sunitinib: a systematic review |
Q34541797 | Osteoporosis and Periodontitis |
Q39185692 | Otorhinolaryngological Toxicities of New Drugs in Oncology |
Q100761762 | Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw |
Q58791940 | Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials |
Q37006852 | Pathophysiology of Osteonecrosis of the Jaws |
Q64070481 | Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England |
Q36125581 | Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw. |
Q38691628 | Periodontal Disease, Dental Implants, Extractions and Medications Related to Osteonecrosis of the Jaws |
Q92557680 | Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw |
Q41161756 | Plasticity of Myeloid Cells during Oral Barrier Wound Healing and the Development of Bisphosphonate-related Osteonecrosis of the Jaw. |
Q48231013 | Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study |
Q34512454 | Position paper on medication-related osteonecrosis of the jaw (MRONJ) |
Q40509688 | Preexisting Periapical Inflammatory Condition Exacerbates Tooth Extraction-induced Bisphosphonate-related Osteonecrosis of the Jaw Lesions in Mice. |
Q56525024 | Prevalence and Risk Factors of Atypical Femoral Fracture Bone Scintigraphic Feature in Patients Experiencing Bisphosphonate-Related Osteonecrosis of the Jaw |
Q57802320 | Prevalence of radiographic findings on jaws exposed to antiresorptive therapy: a meta-analysis |
Q42017254 | Prevention of breast cancer skeletal metastases with parathyroid hormone |
Q36678934 | Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic review |
Q64234600 | Prevention of tooth extraction-triggered bisphosphonate-related osteonecrosis of the jaws with basic fibroblast growth factor: An experimental study in rats |
Q90713668 | Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw |
Q39961852 | Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab |
Q40612308 | Profile of bacteria colonizing the exposed bone of patients with anti-osteoclastic drug-related osteonecrosis of the jaws |
Q58694636 | Prognostic factors for outcome of surgical treatment in medication-related osteonecrosis of the jaw |
Q48517282 | Prosthetic versus surgical rehabilitation in patients with maxillary defect regarding the quality of life: systematic review |
Q100634157 | Quantitative bone single photon emission computed tomography analysis of the effects of duration of bisphosphonate administration on the parietal bone |
Q50929134 | Quantitative ultrasound at the hand phalanges in patients with bisphosphonate-related osteonecrosis of the jaws. |
Q37703472 | Radiographic Findings in Patients with Medication-Related Osteonecrosis of the Jaw. |
Q39226186 | Radiographic evidence of treatment with bisphosphonates |
Q57167005 | Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws |
Q97528401 | Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review |
Q64065276 | Refractory healing after surgical therapy of osteonecrosis of the jaw: associated risk factors in aged patients |
Q37689304 | Relationship between disease stage and renal function in bisphosphonate-related osteonecrosis of the jaw |
Q39169596 | Relevance of Bisphosphonate Therapy in Osteoporosis and Cancer--No Cause for Alarm in Dentistry |
Q90612928 | Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice |
Q48510488 | Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function |
Q38829698 | Resection and microvascular reconstruction of bisphosphonate-related osteonecrosis of the jaw: The role of microvascular reconstruction |
Q92118506 | Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology |
Q38457969 | Response to comments on "diagnosis and management of osteoporosis of the jaw: a systematic review and international consensus". |
Q42338856 | Response to letter to the Editors-Safety of long-term denosumab therapy |
Q92272586 | Review and update on drugs related to the development of osteonecrosis of the jaw |
Q39942547 | Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study |
Q38705715 | Risk factors for medication-related osteonecrosis of the jaws: A systematic review. |
Q64081652 | Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation |
Q39162467 | Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer |
Q92148335 | Risk profile for antiangiogenic agent-related osteonecrosis of the jaws |
Q48294628 | Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw. |
Q36345986 | Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer |
Q51740878 | Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro. |
Q45963261 | Serum levels of RANKL and OPG, and the RANKL/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: Are they useful biomarkers for the advanced stages of osteonecrosis? |
Q47262486 | Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study. |
Q36433392 | Sinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla. |
Q86297959 | Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series |
Q50053219 | Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol |
Q40973749 | Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jaw. |
Q41036893 | Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report |
Q42699567 | Successful Use of Lower-Level Laser Therapy in the Treatment of Medication-Related Osteonecrosis of the Jaw. |
Q40283265 | Successful treatment of osteonecrosis-induced fractured mandible with teriparatide therapy: A case report |
Q35867314 | Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review. |
Q91642357 | Surgical resection for advanced bisphosphonate-related osteonecrosis of the jaw associated with fibrous dysplasia: a case report |
Q51838456 | Surgical treatment of bisphosphonate-related osteonecrosis of the jaws with the use of buccal fat pad: case report. |
Q48155186 | Surgical treatment of stage 2 medication-related osteonecrosis of the jaw compared to osteomyelitis. |
Q38956113 | Surgical treatment vs. conservative treatment in intravenous bisphosphonate-related osteonecrosis of the jaws. Systematic review. |
Q38701111 | Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. |
Q50585784 | Survey on awareness and perceptions of bisphosphonate-related osteonecrosis of the jaw in dental hygienists in Seoul. |
Q61814521 | Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication) |
Q64251161 | Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication) |
Q64071475 | Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (5), utility of bone scintigraphy and F-FDG PET/CT in early detection and risk assessment of medication-related osteonecrosis of the jaw (secondary publication) |
Q64251181 | Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (6), assessment of mandibular metabolism due to long-term administration of an anti-resorptive agent by bone scintigraphy (secondary publication) |
Q91933192 | Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice |
Q92782550 | Task Force on Design and Analysis in Oral Health Research: Medication-Related Osteonecrosis of the Jaw |
Q57300255 | The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention |
Q89884796 | The Effectiveness of the Low-Level Laser, Antibiotic and Surgical Therapy in the Treatment of Medication-Related Osteonecrosis of the Jaws: A Case Report |
Q36292333 | The Prevention of Medication-related Osteonecrosis of the Jaw. |
Q50061309 | The assessment of surgical and non-surgical treatment of stage II medication-related osteonecrosis of the jaw. |
Q37181561 | The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection |
Q90220979 | The effect of bisphosphonate discontinuation on the incidence of postoperative medication-related osteonecrosis of the jaw after tooth extraction |
Q64880479 | The effect of bisphosphonate medication on orthodontics and orthognathic surgery in patients with osteogenesis imperfecta. |
Q36560204 | The effect of bisphosphonates on the endothelial differentiation of mesenchymal stem cells |
Q35697018 | The effect of laser therapy on the expression of osteocalcin and osteopontin after tooth extraction in rats treated with zoledronate and dexamethasone |
Q101038707 | The effect of pamidronate delivery in bisphosphonate-naïve patients on neutrophil chemotaxis and oxidative burst |
Q35910376 | The effect of the duration of intravenous zolendronate medication on the success of non-surgical endodontic therapy: a retrospective study |
Q90220861 | The effects of pentoxifylline and tocopherol in jaw osteomyelitis |
Q55209360 | The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. |
Q89418216 | The influence of geranylgeraniol on microvessel sprouting after bisphosphonate substitution in an in vitro 3D-angiogenesis assay |
Q41706770 | The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). |
Q92267711 | The role of bisphosphonates in orthodontic tooth movement-A review |
Q39975608 | The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis |
Q36107637 | The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature. |
Q41721635 | Therapeutic interactions between mesenchymal stem cells for healing medication-related osteonecrosis of the jaw. |
Q64067509 | Three-dimensional bone evaluation after surgical treatment with plasma rich in growth factors of Medication Related Osteonecrosis of the Jaw (MRONJ): A report of 3 cases |
Q38776007 | Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. |
Q90447697 | Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis |
Q92514549 | Tongue "heart" ulcer from bisphosphonate |
Q38647544 | Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy |
Q99552196 | Treatment of life-threatening acute osteomyelitis of the jaw during chemotherapy: a case report |
Q51084874 | Treatment of medication-related osteonecrosis of the jaws (MRONJ) with ultrasonic piezoelectric bone surgery. A case series of 20 treated sites. |
Q37217775 | Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. |
Q40324652 | Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells. |
Q58578247 | Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review |
Q42177129 | Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report |
Q38979535 | Uncertainty of current algorithm for bisphosphonate-related osteonecrosis of the jaw in population-based studies: a systematic review |
Q36014948 | Usability of surgical treatment in cases of bisphosphonate-related osteonecrosis of the jaw stage 2 with sequestrum |
Q57069083 | Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US |
Q47911313 | Zoledronate Impairs Socket Healing after Extraction of Teeth with Experimental Periodontitis |
Q87055716 | Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep |
Q64236755 | Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis |
Q46272591 | Zoledronic Acid, Bevacizumab and Dexamethasone-Induced Apoptosis, Mitochondrial Oxidative Stress, and Calcium Signaling Are Decreased in Human Osteoblast-Like Cell Line by Selenium Treatment |
Q47559000 | Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis. |
Q52857137 | [Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel]. |
Q93346859 | [Progress on medication-related osteonecrosis of the jaw] |
Q87630095 | [Research progress on bisphosphonate-related osteonecrosis of the jaws] |
Search more.